JP7761373B2 - Ｔｄｐ－４３のｒｎａ認識モチーフ１（ｒｒｍ１）中のエピトープ、およびそれらに対するミスフォールディング選択的抗体 - Google Patents

Ｔｄｐ－４３のｒｎａ認識モチーフ１（ｒｒｍ１）中のエピトープ、およびそれらに対するミスフォールディング選択的抗体

Info

Publication number
JP7761373B2
JP7761373B2 JP2019565224A JP2019565224A JP7761373B2 JP 7761373 B2 JP7761373 B2 JP 7761373B2 JP 2019565224 A JP2019565224 A JP 2019565224A JP 2019565224 A JP2019565224 A JP 2019565224A JP 7761373 B2 JP7761373 B2 JP 7761373B2
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
cdr
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019565224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522475A (ja
JP2020522475A5 (enExample
Inventor
エス． プロトキン，スティーブン
アール． キャッシュマン，ニール
ペン，シュビアオ
Original Assignee
ザ ユニヴァーシティ オブ ブリティッシュ コロンビア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニヴァーシティ オブ ブリティッシュ コロンビア filed Critical ザ ユニヴァーシティ オブ ブリティッシュ コロンビア
Publication of JP2020522475A publication Critical patent/JP2020522475A/ja
Publication of JP2020522475A5 publication Critical patent/JP2020522475A5/ja
Application granted granted Critical
Publication of JP7761373B2 publication Critical patent/JP7761373B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019565224A 2017-05-30 2018-05-30 Ｔｄｐ－４３のｒｎａ認識モチーフ１（ｒｒｍ１）中のエピトープ、およびそれらに対するミスフォールディング選択的抗体 Active JP7761373B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762512647P 2017-05-30 2017-05-30
US62/512,647 2017-05-30
US201762570582P 2017-10-10 2017-10-10
US62/570,582 2017-10-10
US201762595866P 2017-12-07 2017-12-07
US62/595,866 2017-12-07
PCT/CA2018/050634 WO2018218352A1 (en) 2017-05-30 2018-05-30 Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto

Publications (3)

Publication Number Publication Date
JP2020522475A JP2020522475A (ja) 2020-07-30
JP2020522475A5 JP2020522475A5 (enExample) 2021-07-26
JP7761373B2 true JP7761373B2 (ja) 2025-10-28

Family

ID=64454301

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019565224A Active JP7761373B2 (ja) 2017-05-30 2018-05-30 Ｔｄｐ－４３のｒｎａ認識モチーフ１（ｒｒｍ１）中のエピトープ、およびそれらに対するミスフォールディング選択的抗体

Country Status (5)

Country Link
US (2) US11214613B2 (enExample)
EP (1) EP3634987A4 (enExample)
JP (1) JP7761373B2 (enExample)
CA (1) CA3064785A1 (enExample)
WO (1) WO2018218352A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114008073B (zh) * 2019-05-23 2025-08-12 Ac免疫有限公司 抗tdp-43结合分子及其用途
EP3976793A4 (en) * 2019-05-27 2023-06-21 The University of British Columbia CONFORMATION-SPECIFIC EPITOPES IN TAU, ANTIBODIES AGAINST IT AND METHODS RELATED THERETO
US20240050529A1 (en) 2019-10-07 2024-02-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
IL316153A (en) * 2022-04-08 2024-12-01 Ac Immune Sa Anti-tdp-43 binding molecules
WO2025035133A1 (en) * 2023-08-10 2025-02-13 Board Of Regents, The University Of Texas System Bmp-7 antibody compositions & methods for treating cancer
WO2026132413A1 (en) 2024-12-20 2026-06-25 Bioarctic Ab Antibody against tdp-43

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051351A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Method to generate antibodies to ion channels
WO2013061163A2 (en) 2011-10-28 2013-05-02 Biogen Idec International Neuroscience Gmbh Tdp-43 specific binding molecules
WO2016053610A1 (en) 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
WO2016086320A1 (en) 2014-12-05 2016-06-09 UNIVERSITé LAVAL Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012975A1 (en) 1995-10-02 1997-04-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services An epithelial protein and dna thereof for use in early cancer detection
US6472367B1 (en) * 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
EP2342220B1 (en) 2008-10-06 2021-05-12 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
EP3453717A1 (en) * 2010-07-21 2019-03-13 Eastern Virginia Medical School Peptide compounds to regulate the complement system
US9428575B2 (en) * 2012-12-31 2016-08-30 Development Center For Biotechnology Anti-granulysin antibodies and methods of use thereof
US11756650B2 (en) 2015-11-09 2023-09-12 The University Of British Columbia Systems and methods for predicting misfolded protein epitopes by collective coordinate biasing
US20180125920A1 (en) * 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051351A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Method to generate antibodies to ion channels
WO2013061163A2 (en) 2011-10-28 2013-05-02 Biogen Idec International Neuroscience Gmbh Tdp-43 specific binding molecules
WO2016053610A1 (en) 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
WO2016086320A1 (en) 2014-12-05 2016-06-09 UNIVERSITé LAVAL Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
US20200165327A1 (en) 2020-05-28
JP2020522475A (ja) 2020-07-30
WO2018218352A1 (en) 2018-12-06
US20220162293A1 (en) 2022-05-26
EP3634987A1 (en) 2020-04-15
EP3634987A4 (en) 2021-03-03
CA3064785A1 (en) 2018-12-06
US11214613B2 (en) 2022-01-04

Similar Documents

Publication Publication Date Title
US11214613B2 (en) Epitopes in the RNA recognition motif 1 (RRM1) of TDP-43 and misfolding-selective antibodies thereto
AU2022201737B2 (en) Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
US11779629B2 (en) Compositions comprising cyclic peptides derived from an A-beta peptide
US12173055B2 (en) N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
AU2016353553B2 (en) Amyloid beta epitopes and antibodies thereto
US12559548B2 (en) Antibodies to misfolded TDP-43 and methods of use
CA3004493A1 (en) C-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US20180326027A1 (en) Epitopes in amyloid beta and conformationally-selective antibodies thereto
US20080085241A1 (en) Antibody
US20250346655A1 (en) Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
CA3174188A1 (en) Antibodies to misfolded amyloid beta

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230324

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230403

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230501

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251016

R150 Certificate of patent or registration of utility model

Ref document number: 7761373

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150